Education
About Us
Working with TipRanks
Follow Us
Teva Pharmaceutical (TEVA)
NYSE:TEVA
TEVA Stock Chart & Stats
$32.64
$0.18(0.83%)
At close: 4:00 PM EST
$32.64
$0.18(0.83%)
Day’s Range― - ―
52-Week Range$12.47 - $33.42
Previous CloseN/A
Volume1.13M
Average Volume (3M)9.12M
Market Cap
$37.08B
Enterprise Value$38.39B
Total Cash (Recent Filing)$2.20B
Total Debt (Recent Filing)$17.09B
Price to Earnings (P/E)53.3
Beta0.62
Next Earnings
Jan 28, 2026EPS Estimate
0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.78
Shares Outstanding1,146,838,700
10 Day Avg. Volume9,961,762
30 Day Avg. Volume9,116,075
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)4.64
Price to Sales (P/S)1.51
P/FCF Ratio12.16
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue2.29
Enterprise Value/Gross Profit4.57
Enterprise Value/Ebitda10.41
Forecast
1Y Price Target
$36.86Price Target Upside12.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)2.75
Revenue Forecast (FY)$16.84B
Bulls Say, Bears Say
Bulls Say
Non-dilutive Funding And Pipeline MonetizationAnalyst points to a partnership with Royalty Pharma and prior successful monetization deals as evidence that non-dilutive funding can accelerate late-stage programs like the IL15 effort without materially diluting shareholders.
Profitability And MarginsAnalyst projects largely flat revenue alongside improving profitability, supporting a credible margin expansion thesis that could raise the company's earnings quality and valuation.
Strategic GuidanceAnalyst highlights that reaffirmation of medium- and long-term commercial targets demonstrates strategic stability that could improve investor confidence in the company's direction.
Bears Say
Analyst Conflicts Of InterestReport disclosure of multiple business and financial ties to the company raises concerns about potential conflicts of interest that may undermine the objectivity of the research.
Insufficient Analyst TransparencyAnalyst notes that absence of detailed company-specific information in the report limits the ability to extract a clear rationale, creating uncertainty for investors relying on third-party analysis.
Relative Valuation RiskAnalyst warns that the stock appears expensive relative to specialty pharma peers, which could limit upside unless investor perceptions about future growth and risk change.
Teva Pharmaceutical News
TEVA FAQ
What was Teva Pharmaceutical’s price range in the past 12 months?
Teva Pharmaceutical lowest stock price was $12.46 and its highest was $33.42 in the past 12 months.
What is Teva Pharmaceutical’s market cap?
Teva Pharmaceutical’s market cap is $37.08B.
When is Teva Pharmaceutical’s upcoming earnings report date?
Teva Pharmaceutical’s upcoming earnings report date is Jan 28, 2026 which is in 12 days.
How were Teva Pharmaceutical’s earnings last quarter?
Teva Pharmaceutical released its earnings results on Nov 05, 2025. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.09.
Is Teva Pharmaceutical overvalued?
According to Wall Street analysts Teva Pharmaceutical’s price is currently Undervalued.
Does Teva Pharmaceutical pay dividends?
Teva Pharmaceutical pays a Quarterly dividend of $0.085 which represents an annual dividend yield of N/A. See more information on Teva Pharmaceutical dividends here
What is Teva Pharmaceutical’s EPS estimate?
Teva Pharmaceutical’s EPS estimate is 0.64.
How many shares outstanding does Teva Pharmaceutical have?
Teva Pharmaceutical has 1,146,838,700 shares outstanding.
What happened to Teva Pharmaceutical’s price movement after its last earnings report?
Teva Pharmaceutical reported an EPS of $0.78 in its last earnings report, beating expectations of $0.69. Following the earnings report the stock price went up 20.235%.
Which hedge fund is a major shareholder of Teva Pharmaceutical?
Currently, no hedge funds are holding shares in TEVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teva Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.86 (12.93% Upside)
$36.86 (12.93% Upside)
Blogger Sentiment
Bullish
TEVA Sentiment 87%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.57%
12-Months-Change
Fundamentals
Return on Equity
10.77%
Trailing 12-Months
Asset Growth
-4.55%
Trailing 12-Months
Company Description
Teva Pharmaceutical
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
TEVA Company Deck
TEVA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Teva demonstrated strong growth in its innovative portfolio and significant debt reduction, reinforcing confidence in long-term targets. However, challenges remain in the TAPI segment, European generics, and declining free cash flow, which offset some of the positive developments.View all TEVA earnings summariesTEVA Revenue Breakdown
54.45% North America
32.42% Europe
13.12% International Markets
TEVA Stock 12 Month Forecast
Average Price Target
$36.86
▲(12.93% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Neurocrine
―
Perrigo Company
―
Amneal Pharmaceuticals
―
Ownership Overview
0.39% Insiders
4.91% Mutual Funds
0.27% Other Institutional Investors
89.77% Public Companies and Individual Investors